Ca2+-dependent splicing of neurexin IIα G Rozic-Kotliroff, N Zisapel Biochemical and biophysical research communications 352 (1), 226-230, 2007 | 59 | 2007 |
Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients M Leiba, S Malkiel, I Budnik, G Rozic, A Avigdor, A Duek, A Nagler, ... Blood Cells, Molecules, and Diseases 65, 1-7, 2017 | 37 | 2017 |
Dynamic changes in neurexins' alternative splicing: role of Rho-associated protein kinases and relevance to memory formation G Rozic, Z Lupowitz, Y Piontkewitz, N Zisapel PloS one 6 (4), e18579, 2011 | 37 | 2011 |
Translocation t (11; 14) in newly diagnosed patients with multiple myeloma: Is it always favorable? M Leiba, A Duek, N Amariglio, A Avigdor, N Benyamini, I Hardan, ... Genes, Chromosomes and Cancer 55 (9), 710-718, 2016 | 36 | 2016 |
Exonal elements and factors involved in the depolarization-induced alternative splicing of neurexin 2 G Rozic, Z Lupowitz, N Zisapel Journal of Molecular Neuroscience 50, 221-233, 2013 | 23 | 2013 |
Alternative splicing of neurexins: a role for neuronal polypyrimidine tract binding protein M Resnick, A Segall, Z Lupowitz, N Zisapel Neuroscience letters 439 (3), 235-240, 2008 | 21 | 2008 |
A multifunctional 5-aminolevulinic acid derivative induces erythroid differentiation of K562 human erythroleukemic cells G Berkovitch-Luria, S Yakobovitch, M Weitman, A Nudelman, G Rozic, ... European journal of pharmaceutical sciences 47 (1), 206-214, 2012 | 11 | 2012 |
Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft N Tarasenko, A Nudelman, G Rozic, SM Cutts, A Rephaeli Investigational new drugs 35, 412-426, 2017 | 9 | 2017 |
Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t … A Duek, L Trakhtenbrot, N Amariglio, N Benyamini, I Zilbershats, C Ganzel, ... Genes, Chromosomes and Cancer 58 (8), 516-520, 2019 | 8 | 2019 |
The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo G Rozic, L Paukov, J Jakubikova, D Ben-Shushan, A Duek, A Leiba, ... Oncotarget 7 (38), 62572, 2016 | 6 | 2016 |
STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models G Rozic, L Paukov, Z Cohen, I Shapira, A Duek, O Bejamini, A Avigdor, ... Oncotarget 9 (59), 31367, 2018 | 5 | 2018 |
Bi-functional prodrugs of 5-aminolevulinic acid and butyric acid increase erythropoiesis in anemic mice in an erythropoietin-independent manner A Rephaeli, N Tarasenko, E Fibach, G Rozic, I Lubin, J Lipovetsky, ... European Journal of Pharmaceutical Sciences 91, 91-97, 2016 | 5 | 2016 |
Compositions and methods for treating hematological malignancies M Leiba, G Rozic US Patent 9,782,387, 2017 | 2 | 2017 |
STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy G Rozic, P Lena, J Jakubikova, D Adrian, A Avigdor, A Nagler, M Leiba Blood 126 (23), 5348, 2015 | 1 | 2015 |
Monoallelic Deletion of the Whole Locus of Immunoglobulin Heavy Chain Gene [Del (IGH)] Is Associated with a Better Prognosis in Newly Diagnosed Multiple Myeloma L Trakhtenbrot, A Duek, N Amariglio, A Avigdor, N Benyamini, I Hardan, ... Blood 130 (Supplement 1), 5368-5368, 2017 | | 2017 |
STK405759 as a novel drug for Multiple Myeloma therapy G Rozic, J Jakubikova, L Paukov, A Duek, A Avigdor, A Nagler, M Leiba Clinical Lymphoma, Myeloma and Leukemia 15, e234-e235, 2015 | | 2015 |
THE NOVEL MOLECULE STK405759 HAS SELECTIVE CYTOTOXICITY AGAINST MULTIPLE MYELOMA IN VITRO AND IN VIVO G Rozic, J Jakubikova, A Duek, A Avigdor, A Nagler, M Leiba HAEMATOLOGICA 100, 500-500, 2015 | | 2015 |
Dynamic Changes in Neurexins’ Alternative Splicing: Role of Rho-Associated Protein Kinases and G Rozic, Z Lupowitz, Y Piontkewitz, N Zisapel | | 2011 |
INVOLVEMENT OF SIGNAL TRANSDUCTION PATHWAYS IN ALTERNATIVE SPLICING OF NEUREXIN 2 IN BRAIN NEURONS G Rozic, N Zisapel NEUROPEPTIDES 43 (2), 173-174, 2009 | | 2009 |